Patritumab Deruxtecan for prostatic neoplasms

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 2 trial. Mid-stage trial in people. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 15 Dec 2023: Trial registered, NCT06172478
  2. 26 Feb 2024: Trial started, NCT06172478

The trials

NCT06172478: A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors

State
Under way
Phase
Phase 2
People
890 planned
Started
26 Feb 2024
Primary completion
19 Nov 2030
Arms
HER3-DXd Monotherapy
Results
None posted
  1. 15 Dec 2023: Trial registered
  2. 26 Feb 2024: Trial started

How the status changed

  1. 19 Nov 2026: First set: Phase 2 trial

About the treatment

Kind of treatment: Drug.

Also known as HER3-DXd, HER3-DXd (CTM-1 Lyo-DP), HER3-DXd (CTM-3 Lyo-DP), HER3-DXd (FL-DP), Patritumab Deruxtecan (Fixed dose), Patritumab Deruxtecan (Up-Titration).

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.